Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

231.52USD
29 Sep 2016
Change (% chg)

$-6.27 (-2.64%)
Prev Close
$237.79
Open
$237.05
Day's High
$238.13
Day's Low
$231.42
Volume
1,817,364
Avg. Vol
3,158,813
52-wk High
$322.68
52-wk Low
$195.50

Latest Key Developments (Source: Significant Developments)

Allergan unlikely to pursue Biogen deal- CNBC,citing source
Tuesday, 2 Aug 2016 04:15pm EDT 

: Allergan unlikely to pursue Biogen deal- CNBC,citing source (Bengaluru Newsroom: +1-646-223-8780).  Full Article

Allergan completes divestiture of global generics business to Teva Pharmaceuticals
Tuesday, 2 Aug 2016 12:41pm EDT 

Allergan PLC : Allergan PLC completes divestiture of Global Generics Business to Teva Pharmaceuticals . Company to provide updated guidance as part of Q2 2016 earnings . Plans to commence its previously announced share repurchase program of up to $10 billion of company's common stock in coming days .Company expects to execute an initial $5 billion in open market repurchases over remainder of 2016.  Full Article

Teva gets U.S. FTC clearance for Actavis Generics deal
Wednesday, 27 Jul 2016 02:36pm EDT 

Teva Pharmaceutical Industries Ltd : Teva receives clearance from the U.S. Federal Trade Commission for Actavis Generics acquisition . Has satisfied regulatory approval requirements under purchase agreement to complete acquisition of Actavis Generics .Transaction is expected to close next week.  Full Article

Allergan receives positive opinion for its treatment for IBS-D in adults
Monday, 25 Jul 2016 11:30am EDT 

Allergan Plc : Allergan receives positive opinion for Truberzi® (eluxadoline) for treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults . Truberzi® was generally well tolerated with most common side effects being nausea, constipation, and abdominal pain . Final decision from European Commission on Truberzi is expected within a few months .If approved, anticipate launching Truberzi in Europe during 2017, following negotiations with relevant national payer,reimbursement groups.  Full Article

Allergan and Adamas says FDA approved new, expanded label for Namzaric
Tuesday, 19 Jul 2016 07:59am EDT 

Allergan Plc : In addition to two currently available dosage strengths, two new Namzaric dosage strengths will be available in pharmacies in September. . Allergan and Adamas announce new expanded indication for Namzaric (Memantine and Donepezil Hydrochlorides) extended release for the treatment of moderate to severe Alzheimer's .disease.  Full Article

Allergan files application for approval of oculeve intranasal tear neurostimulator
Monday, 18 Jul 2016 08:05am EDT 

Allergan Plc :Allergan files application to FDA for approval of oculeve intranasal tear neurostimulator.  Full Article

Allergan spokesman says antitrust clearance is "imminent"
Wednesday, 13 Jul 2016 10:10am EDT 

: Allergan Spokesman says in emailed statement that antitrust clearance is "imminent" and agrees with Teva view that deal closing is "any time now" (Reporting By Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

Allergan, Teva deal approval expected in next 2 weeks - CNBC
Wednesday, 13 Jul 2016 09:00am EDT 

: Allergan, Teva deal approval expected in next 2 weeks - CNBC citing sources Further company coverage: [AGN.N TEVA.TA] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Allergan receives positive opinion through European decentralised procedure for belkyra
Friday, 1 Jul 2016 07:30am EDT 

Allergan Plc : Allergan receives positive opinion through European decentralised procedure for belkyra (deoxycholic acid) for patients with submental fullness .Allergan will work to secure national marketing authorisations in concerned member states.  Full Article

Allergan says FDA accepts premarket notification filing for glaucoma treatment
Wednesday, 15 Jun 2016 07:31am EDT 

Allergan Plc : "Look forward to working together with FDA" to bring glaucoma treatment system to market .Allergan announces FDA acceptance of the 510(k) premarket notification filing for the XEN glaucoma treatment system.  Full Article

BRIEF-Allergan issues statement on Namenda XR patent litigation following announcement of ANDA approvals

* Company has settled with all other Namenda XR ANDA defendants, including Lupin Limited and Lupin Pharmaceuticals Inc